Monopar Announces Radiopharma Presentation Selected for Society of Nuclear Medicine and Molecular Imaging 2024 Annual Meeting
Monopar Announces Radiopharma Presentation Selected for Society of Nuclear Medicine and Molecular Imaging 2024 Annual Meeting
WILMETTE, Ill., April 18, 2024 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage biopharmaceutical company focused on developing innovative treatments for cancer patients, today announced that its abstract on the preclinical data for its radiopharmaceutical program MNPR-101-Zr (MNPR-101 conjugated to zirconium-89) submitted to the Society of Nuclear Medicine and Molecular Imaging (SNMMI) 2024 Annual Meeting has been selected for a presentation. SNMMI 2024, held in Toronto, Canada, is recognized as the premier educational, scientific, and research event in the radiopharma space.
Meeting Details:
Event: Society of Nuclear Medicine and Molecular Imaging (SNMMI) 2024 Annual Meeting
Date: June 8 – June 11, 2024
Location: Metro Toronto Convention Centre, Toronto, ON, Canada
About Monopar Therapeutics Inc.
Monopar Therapeutics is a clinical-stage biopharmaceutical company focused on developing innovative treatments for cancer patients. Monopar's pipeline consists of Phase 1-stage MNPR-101 for radiopharmaceutical use in various advanced cancers; Phase 1b-stage camsirubicin for the treatment of advanced soft tissue sarcoma; and an early-stage camsirubicin analog, MNPR-202. For more information, visit: and ir.monopartx.com/presentations.
CONTACT:
Monopar Therapeutics Inc.
Investor Relations
Kim R. Tsuchimoto
Chief Financial Officer
kimtsu@monopartx.com
Follow Monopar on social media for updates:
Twitter: @MonoparTx LinkedIn: Monopar Therapeutics
WILMETTE, Ill., April 18, 2024 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage biopharmaceutical company focused on developing innovative treatments for cancer patients, today announced that its abstract on the preclinical data for its radiopharmaceutical program MNPR-101-Zr (MNPR-101 conjugated to zirconium-89) submitted to the Society of Nuclear Medicine and Molecular Imaging (SNMMI) 2024 Annual Meeting has been selected for a presentation. SNMMI 2024, held in Toronto, Canada, is recognized as the premier educational, scientific, and research event in the radiopharma space.
伊利諾伊州威爾梅特，2024年4月18日（GLOBE NEWSWIRE）——專注於爲癌症患者開發創新療法的臨床階段生物製藥公司Monopar Therapeutics Inc.（納斯達克股票代碼：MNPR）今天宣佈，其放射性藥物項目mnPR-101-ZR（與鋯89偶聯的 MNPR-101）的臨床前數據摘要已提交給協會核醫學與分子成像（SNMMI）2024年年會已入選演講。在加拿大多倫多舉行的SNMMI 2024被公認爲放射性藥物領域首屈一指的教育、科學和研究活動。
Meeting Details:
會議詳情：
Event: Society of Nuclear Medicine and Molecular Imaging (SNMMI) 2024 Annual Meeting
活動：核醫學與分子影像學會 (SNMMI) 2024 年年會
Date: June 8 – June 11, 2024
日期：2024 年 6 月 8 日至 6 月 11 日
Location: Metro Toronto Convention Centre, Toronto, ON, Canada
地點：加拿大安大略省多倫多市大多倫多會議中心
About Monopar Therapeutics Inc.
關於 Monopar Therapeutics Inc.
Monopar Therapeutics is a clinical-stage biopharmaceutical company focused on developing innovative treatments for cancer patients. Monopar's pipeline consists of Phase 1-stage MNPR-101 for radiopharmaceutical use in various advanced cancers; Phase 1b-stage camsirubicin for the treatment of advanced soft tissue sarcoma; and an early-stage camsirubicin analog, MNPR-202. For more information, visit: and ir.monopartx.com/presentations.
Monopar Therapeutics是一家臨床階段的生物製藥公司，專注於爲癌症患者開發創新療法。Monopar 的產品線包括用於治療各種晚期癌症的放射性藥物的 1 期 MNPR-101；用於治療晚期軟組織肉瘤的 1b 期 camsirubicin；以及早期的 camsirubicin 類似物 MNPR-202。欲了解更多信息，請訪問： 和 ir.monopartx.com/presentations。
CONTACT:
聯繫人：
Monopar Therapeutics Inc.
Investor Relations
Kim R. Tsuchimoto
Chief Financial Officer
kimtsu@monopartx.com
Monopar Therapeutics Inc.
投資者關係
金·土本博士
首席財務官
kimtsu@monopartx.com
Follow Monopar on social media for updates:
請在社交媒體上關注 Monopar 獲取最新消息：
Twitter: @MonoparTx LinkedIn: Monopar Therapeutics
推特： @MonoparTx 領英： Monopar 療法
譯文內容由第三人軟體翻譯。
風險及免責聲明
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用瀏覽器的分享功能，分享給你的好友吧